Catumaxomab

Removab

0.1 MG / ML SolutionCanadaCancelled

This page is kept for reference and is not offered to search engines.

In other countries

The same active substances on other registers, the same brand first.

RemovabEuropean Union · Neovii Biotech GmbHSame brand
Korjuny 10 Microgramos Concentrado Para Solucion Para PerfusionSpain · 10 µg · concentrado para solución para perfusión · Atnahs Pharma Netherlands Bv.Same substance
Korjuny 50 Microgramos Concentrado Para Solucion Para PerfusionSpain · 50 µg · concentrado para solución para perfusión · Atnahs Pharma Netherlands Bv.Same substance
KorjunyEuropean Union · Atnahs Pharma Netherlands B.V.Same substance
KorjunyCroatiaSame substance

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Catumaxomab

Removab

0.1 MG / ML SolutionCanadaCancelled

Open in the registerAsk Osler about it

This page is kept for reference and is not offered to search engines.

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Korjuny 10 microgram concentraat voor oplossing voor infusieNetherlands · Concentraat voor oplossing voor infusie · Atnahs Pharma Netherlands B.V.

Korjuny 50 microgram, concentraat voor oplossing voor infusieNetherlands · Concentraat voor oplossing voor infusie · Atnahs Pharma Netherlands B.V.

Documents

The official texts, at the regulator.

Register entryHealth Canada

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Health Canada, Canada

Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.

Licence: Open Government Licence Canada · Added 13 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Catumaxomab
Strength: 0.1 MG / ML
Dosage form: Solution
Route: Intraperitoneal
Register: Canada (Health Canada)
Status: Cancelled
Status in the register: Cancelled Pre Market
Registration: DIN 02385724
Marketing authorisation holder: Fresenius Biotech GMBH
ATC code: L01FX03
Group: Antineoplastic and immunomodulating agents
Supply: PRESCRIPTION, SCHEDULE D